Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
SOUTH SAN FRANCISCO, Calif., March 01, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:
- Cowen and Company’s 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. Eastern Time in Boston.
- Oppenheimer’s 27th Annual Healthcare Conference on Wednesday, March 22, 2017, at 1:35 p.m. Eastern Time in New York.
Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
